Ahead of Friday's FDA Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) meeting, briefing materials have been posted related to the biologic license application (BLA) for Natpara (rhPTH[1-84]) developed by NPS Pharmaceuticals Inc., of Bedminster, N.J.